Byoung-Chul Lee is the founder of Kanaph Therapeutics. Kanaph Therapeutics has raised $73M in total funding. Latest round: Series C.
Byoung-Chul Lee is the founder and CEO of Kanaph Therapeutics, a biotech venture focused on developing immuno-oncology therapies through its proprietary TMEkine™ platform and other drug fusion technologies. The company has successfully raised over KRW 30 billion in cumulative external funding within two years of its founding and an additional KRW 23 billion in a Series C round. Prior to Kanaph Therapeutics, Lee gained extensive experience in antibody drug development, including work on antibody–drug conjugates (ADCs) and bispecific antibody therapeutics at Genentech and Santen.
Full founder directory · Investor directory · Company funding database · Fundraising library